Jove
Visualize
Contact Us

Related Experiment Videos

Do preclinical testing strategies help predict human hepatotoxic potentials?

Terry S Peters1

  • 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland 20857, USA. peterst@cder.fda.gov

Toxicologic Pathology
|April 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Comparison of Standard Clinical Pathology Parameter Values in Fasted and Fed Rats and Non-human Primates.

Toxicologic pathology·2026
Same journal

Time-Dependent Autolysis in Ex Vivo-Maintained Rat Tissue in Saline: A Descriptive Study and Practical Guidance for Histopathologic Assessment.

Toxicologic pathology·2026
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Preclinical drug testing in animals often fails to predict overt hepatotoxicity in humans. This study examines why animal models are limited and discusses drugs that caused liver injury post-approval.

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Development

Background:

  • Overt hepatotoxicity is a significant concern in drug development.
  • Preclinical testing aims to identify drug-induced risks before human exposure.
  • Current animal models have limitations in predicting human-specific adverse effects.

Purpose of the Study:

  • To evaluate the effectiveness of preclinical animal models in predicting drug-induced hepatotoxicity.
  • To explore reasons for the failure of animal models to predict human liver injury.
  • To discuss specific drug examples that exhibited hepatotoxicity after market approval.

Main Methods:

  • Review of standard preclinical drug testing protocols involving rodent and non-rodent species.
  • Analysis of case studies of drugs that caused significant hepatotoxicity despite preclinical testing.

Related Experiment Videos

  • Examination of factors contributing to the lack of predictivity in animal models.

    • Main Results:

    • Preclinical animal models are not always predictive of human hepatotoxicity.
    • Factors like genetic sensitivity, immune responses, and idiosyncratic reactions limit model accuracy.
    • Several drugs have reached the market and later shown severe liver adverse effects.

    Conclusions:

    • Animal models have inherent limitations in detecting all forms of drug-induced hepatotoxicity.
    • Continued vigilance and post-market surveillance are crucial for drug safety.
    • Understanding these limitations is vital for improving drug development and regulatory processes.